Company Aggregate Debt: merus.nl (MRUS)

Merus N.V. (MRUS) develops advanced bispecific antibodies to combat female tumors, which underscores the company's overall commitment. Positive test dynamics are currently supporting the share price, although the market is awaiting the start of sales. The project's success depends on FDA approval of Zeno and the cash burn rate, while the value of 0.02 captures this debt load metric.

Company Aggregate Debts: Merus (MRUS) for 07/04/2022 - 01/10/2026

Analytical breakdowns and data insights for company Merus (MRUS)

- price and consensus price forecast:

Stock Price Merus Therapeutics|MRUS - Price Target Chart

- market capitalization data:

Market Capitalization Merus Corp|MRUS - Enterprise Value

- book capitalization data:

Accounting Value per Share Merus|MRUS - Book Capitalization|Market-to-Book Ratio merus.nl|MRUS - Aggregate Company Assets

- debt and liquidity data:

All Debt to Shareholders' Equity Ratio Merus N.V.|MRUS - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Merus NV|MRUS - Company Total Debt|Debt to Book Value Merus Corp

Summary company analytics:Merus Therapeutics MRUS

The survival of Merus N.V. (MRUS) depends directly on the outcome of clinical trials and the rate of capital burn amid fierce competition in oncology. This indicator aggregates all borrowed funds, reflecting the real-time market value of liabilities, which allows for an assessment of bankruptcy risk through the company's current liabilities in the absence of revenue or delays in regulatory approvals.

Competitor analysis for Merus N.V.